RIDGEFIELD, Conn., January 28, 2026 – Today, Boehringer Ingelheim and the Detect the SOS Collective, a group of professional organizations, advocates, patients and caregivers, launched a new public health mission: elevate awareness of urine albumin-to-creatinine ratio (uACR) screening to help uncover hidden risks for chronic kidney disease (CKD) and related cardiovascular (CV) events like heart attack or stroke. 

Leading healthcare organizations* recommend routine screening with the uACR test, as well as the estimated glomerular filtration rate (eGFR) test, for individuals with high blood pressure, diabetes or other CKD risk factors. However, uACR screening — a simple urine test that can help uncover a potentially modifiable sign of kidney damage early — is often underutilized. As a result, many of these at-risk individuals may be missing a hidden signal from their kidneys — an SOS that may be alerting them to an increased risk for major CV events like heart attack or stroke.